Karyopharm Therapeutics Stock Analysis

Karyopharm Stock Analysis Notes

About 43.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 11.49. Karyopharm Therapeutics had not issued any dividends in recent years. The entity had 1:15 split on the 26th of February 2025. Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. Karyopharm Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 442 people. To find out more about Karyopharm Therapeutics contact Richard MBA at 617 658 0600 or learn more at https://www.karyopharm.com.

Karyopharm Therapeutics Investment Alerts

Karyopharm Therapeutics Upcoming and Recent Events

Karyopharm Largest EPS Surprises

View All Earnings Estimates

Karyopharm Therapeutics Environmental, Social, and Governance (ESG) Scores

Karyopharm Therapeutics Thematic Classifications

Karyopharm Stock Institutional Investors

Note, although Karyopharm Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Karyopharm Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 34.73 M.

Karyopharm Profitablity

The company has Profit Margin (PM) of (0.44) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.11.

Management Efficiency

Karyopharm Therapeutics has return on total asset (ROA) of (0.4476) % which means that it has lost $0.4476 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9105) %, meaning that it created substantial loss on money invested by shareholders. Karyopharm Therapeutics' management efficiency ratios could be used to measure how well Karyopharm Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The Karyopharm Therapeutics' current Return On Equity is estimated to increase to 0.43, while Return On Tangible Assets are projected to decrease to (0.49). As of now, Karyopharm Therapeutics' Asset Turnover is increasing as compared to previous years.

Technical Drivers

As of the 23rd of July, Karyopharm Therapeutics secures the Mean Deviation of 4.4, downside deviation of 5.87, and Risk Adjusted Performance of 0.0215. Karyopharm Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.

Karyopharm Therapeutics Price Movement Analysis

Karyopharm Therapeutics Insider Trading Activities

Karyopharm Therapeutics Outstanding Bonds

Karyopharm Therapeutics Predictive Daily Indicators

Karyopharm Therapeutics Forecast Models

Karyopharm Therapeutics' time-series forecasting models are one of many Karyopharm Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Karyopharm Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Karyopharm Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Karyopharm shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Karyopharm Therapeutics. By using and applying Karyopharm Stock analysis, traders can create a robust methodology for identifying Karyopharm entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Karyopharm analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Karyopharm analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Karyopharm Therapeutics stock analysis indicators help investors evaluate how Karyopharm Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Karyopharm Therapeutics shares will generate the highest return on investment. By understating and applying Karyopharm Therapeutics stock analysis, traders can identify Karyopharm Therapeutics position entry and exit signals to maximize returns.

When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.